Market Research Logo

Scar - Pipeline Review, H2 2016

Scar - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Scar - Pipeline Review, H2 2016’, provides an overview of the Scar pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Scar, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Scar and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Scar
    • The report reviews pipeline therapeutics for Scar by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Scar therapeutics and enlists all their major and minor projects
    • The report assesses Scar therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Scar
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Scar
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Scar Overview
    Therapeutics Development
    Pipeline Products for Scar - Overview
    Pipeline Products for Scar - Comparative Analysis
    Scar - Therapeutics under Development by Companies
    Scar - Therapeutics under Investigation by Universities/Institutes
    Scar - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Scar - Products under Development by Companies
    Scar - Products under Investigation by Universities/Institutes
    Scar - Companies Involved in Therapeutics Development
    3M Drug Delivery Systems
    Albireo AB
    Altacor Limited
    Beech Tree Labs, Inc.
    Clanotech AB
    Escape Therapeutics, Inc.
    FirstString Research, Inc.
    LegoChem Biosciences, Inc
    Moerae Matrix, Inc.
    Promore Pharma
    RXi Pharmaceuticals Corporation
    VBS Pharmaceuticals
    Scar - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    A-3914 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    A-5425 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BTL-slo - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CLT-28643 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    decorin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FibroStem - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FS-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Granexin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ICX-RHY - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LCB-030110 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MG-53 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MMI-0100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nefopam hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OLX-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Polysaccharide for Wounds and Scars - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PXL-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Scar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RXI-109 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-34240 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tranilast - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Scar - Dormant Projects
    Scar - Discontinued Products
    Scar - Product Development Milestones
    Featured News & Press Releases
    Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream
    Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
    Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
    Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109
    Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
    Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference
    Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics
    Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting
    Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO
    Sep 29, 2015: RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference
    Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109
    Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
    Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology
    Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301
    Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Scar, H2 2016
    Number of Products under Development for Scar - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Scar - Pipeline by 3M Drug Delivery Systems, H2 2016
    Scar - Pipeline by Albireo AB, H2 2016
    Scar - Pipeline by Altacor Limited, H2 2016
    Scar - Pipeline by Beech Tree Labs, Inc., H2 2016
    Scar - Pipeline by Clanotech AB, H2 2016
    Scar - Pipeline by Escape Therapeutics, Inc., H2 2016
    Scar - Pipeline by FirstString Research, Inc., H2 2016
    Scar - Pipeline by LegoChem Biosciences, Inc, H2 2016
    Scar - Pipeline by Moerae Matrix, Inc., H2 2016
    Scar - Pipeline by Promore Pharma, H2 2016
    Scar - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
    Scar - Pipeline by VBS Pharmaceuticals, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Scar - Dormant Projects, H2 2016
    Scar - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Scar, H2 2016
    Number of Products under Development for Scar - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report